150 related articles for article (PubMed ID: 25016625)
1. Ibrutinib approved for the treatment of mantle cell lymphoma.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):808. PubMed ID: 25016625
[No Abstract] [Full Text] [Related]
2. Ibrutinib approved for mantle cell lymphoma.
Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous development of zanubrutinib in the USA and China.
Li G; Liu X; Chen X
Nat Rev Clin Oncol; 2020 Oct; 17(10):589-590. PubMed ID: 32651571
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
Styskel BA; Lopez-Mattei J; Jimenez CA; Stewart J; Hagemeister FB; Faiz SA
Am J Respir Crit Care Med; 2019 Jun; 199(12):e43-e44. PubMed ID: 30802411
[No Abstract] [Full Text] [Related]
5. Can we improve on ibrutinib in mantle cell lymphoma?
Rule S
Lancet Haematol; 2018 Mar; 5(3):e98-e99. PubMed ID: 29396093
[No Abstract] [Full Text] [Related]
6. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
Lee HJ; Schmelz JL; Cramer F; Romaguera JE; Badillo M; Wang M
Br J Haematol; 2020 Mar; 188(6):e94-e98. PubMed ID: 32057090
[No Abstract] [Full Text] [Related]
7. Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?
Martin P
Lancet; 2016 Feb; 387(10020):728-9. PubMed ID: 26673812
[No Abstract] [Full Text] [Related]
8. [Mantle cell lymphoma of the iris treated by ibrutinib].
Sales De Gauzy T; Oberic L; Fournié P; Soler V
J Fr Ophtalmol; 2018 Dec; 41(10):e501-e502. PubMed ID: 30449641
[No Abstract] [Full Text] [Related]
9. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Zhang L; Newberry KJ; Wang M
Expert Rev Clin Immunol; 2013 Jun; 9(6):495-7. PubMed ID: 23730878
[No Abstract] [Full Text] [Related]
10. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
11. Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.
Mancebo SE; Smith JR; Intlekofer AM; Zelenetz AD; Myskowski PL
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e113-5. PubMed ID: 25499623
[No Abstract] [Full Text] [Related]
12. Ibrutinib: a force with a dark side?
Smith MR
Blood; 2016 Mar; 127(12):1523-4. PubMed ID: 27013210
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
de Claro RA; McGinn KM; Verdun N; Lee SL; Chiu HJ; Saber H; Brower ME; Chang CJ; Pfuma E; Habtemariam B; Bullock J; Wang Y; Nie L; Chen XH; Lu DR; Al-Hakim A; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Aug; 21(16):3586-90. PubMed ID: 26275952
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Kaur V; Swami A
J Oncol Pharm Pract; 2017 Apr; 23(3):235-239. PubMed ID: 26970573
[TBL] [Abstract][Full Text] [Related]
15. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
[No Abstract] [Full Text] [Related]
16. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
Lee HJ; Chihara D; Wang M; Mouhayar E; Kim P
Leuk Lymphoma; 2016 Dec; 57(12):2914-2916. PubMed ID: 27087288
[No Abstract] [Full Text] [Related]
17. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Hernández-Rivas JÁ; Qi K; Deshpande S; Parisi L; Wang M
Haematologica; 2019 May; 104(5):e211-e214. PubMed ID: 30442728
[No Abstract] [Full Text] [Related]
19. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
20. Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
Law YXT; Lee LS
JAMA Oncol; 2018 Jan; 4(1):118-119. PubMed ID: 28910460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
